期刊
JOURNAL OF CONTROLLED RELEASE
卷 74, 期 1-3, 页码 295-302出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/S0168-3659(01)00341-8
关键词
doxorubicin; anticancer drug; drug targeting; polymeric micelle
We show the result of pre-clinical study of NK911, a polymeric micelle carrier system for doxorubicin (DOX). The NK911 micelle carrier consists of polyethyleneglycol and conjugated doxorubicin-polyaspartic acid. It has high hydrophobic inner core, and therefore can entrap the sufficient amount of DOX. NK911 has a small particle size of about 40 nm in diameter that accumulates in tumor tissue by EPR effect showing much stronger activity than the free DOX. We plan to perform a clinical trial at National Cancer Center Hospital, Japan from 2001. (C) 2001 Elsevier Science BY. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据